Tom Strange
Investitore di Private Equity presso iCON Infrastructure LLP
Posizioni attive di Tom Strange
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
iCON Infrastructure LLP
 iCON Infrastructure LLP Investment ManagersFinance iCON Infrastructure LLP is a private equity firm founded in 2004 by Paul Malan. The firm is headquartered in London, United Kingdom with offices in Germany, Canada and the United States. | Investitore di Private Equity | 01/06/2023 | - |
Storia della carriera di Tom Strange
Precedenti posizioni note di Tom Strange
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
MiroBio Ltd.
 MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Investitore di Private Equity | 01/04/2022 | 01/11/2022 |
Formazione di Tom Strange
| University of Cambridge | Graduate Degree |
| The University of Nottingham | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Regno Unito | 4 |
| Stati Uniti | 2 |
Posizioni
| Private Equity Investor | 2 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Settori
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
iCON Infrastructure LLP
iCON Infrastructure LLP Investment ManagersFinance iCON Infrastructure LLP is a private equity firm founded in 2004 by Paul Malan. The firm is headquartered in London, United Kingdom with offices in Germany, Canada and the United States. | Finance |
MiroBio Ltd.
MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Tom Strange
- Esperienza
